Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology

Executive Summary

Merck’s strong Phase II data testing Keytruda with chemotherapy in first-line lung cancer may put pressure on future IO/IO combinations when it comes to toxicity, efficacy and – importantly – cost.

Advertisement

Related Content

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Under Fire, Bristol Plans To Pick Up The IO Pieces
Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
PD-1 Deep Dive: Lung Cancer Market Braced For Change
AstraZeneca Clinical Hold Could Be No Real Concern, Or Very Bad For AZ And BMS
Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
Does CheckMate 026 Take Bristol Out Of The End Game?
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
What's Next For Bristol's Opdivo/Yervoy Combination

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel